Drug Trial Radar · NCT02605174
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
Last checked: Nov 20, 2026Latest source record: Sep 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,005
Actual
Start
May 2016
Primary completion
Jun 30, 2017
Study completion Jun 30, 2017
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- CoLucid Pharmaceuticals
- First posted
- Nov 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
Conditions
- Migraine With or Without Aura
Interventions
Lasmiditan 50 mgDrug
One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)
Lasmiditan 100 mgDrug
One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)
Lasmiditan 200 mgDrug
One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)
PlaceboDrug
Two placebo tablets to match lasmiditan doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Headache Pain Free at 2 Hours Post DoseTime frame: 2 hours post dose
- Percentage of Participants Who Are Most Bothersome Symptom (MBS) FreeTime frame: 2 hours post dose
Locations
95 sites in 1 country. Site status is shown where the registry gives one.
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama
Medical Affiliated Research Center, Inc. - ARC
Huntsville, Alabama
21st Century Neurology
Phoenix, Arizona
Anaheim Clinical Trials
Anaheim, California
The Research Center of Southern California
Carlsbad, California
eStudySite
Chula Vista, California
Pharmacology Research Institute
Los Alamitos, California
Pharmacology Research Institute, Newport Beach
Newport Beach, California
Pacific Research Partners
Oakland, California
Desert Valley Research
Rancho Mirage, California
Northern California Clinical Research Center
Redding, California
Anderson Clinical Research
Redlands, California
California Research Foundation
San Diego, California
Neurological Research Institute
Santa Monica, California
Schuster Medical Research Institute
Sherman Oaks, California
Encompass Clinical Research
Spring Valley, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Lytle and Weiss, PLLC dba Clinical Trials of the Rockies
Denver, Colorado
Comprehensive Psychiatric Care
Norwich, Connecticut
Chase Medical Research, LLC
Waterbury, Connecticut
Nova Clinical Reseach, LLC
Bradenton, Florida
PAB Clinical Research
Brandon, Florida
Meridien Research
Brooksville, Florida
Avail Clinical Research, LLC
DeLand, Florida
The Core Research
Doral, Florida
Clinical Research West Coast
Fort Myers, Florida
Indago Research & Health Center, Inc.
Hialeah, Florida
Infinity Clinical Research, LLC
Hollywood, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Florida Clinical Research
Maitland, Florida
Pharmax Research Clinic, Inc.
Miami, Florida
Prestige Clinical Research Center, Inc.
Miami, Florida
Floriday Medical Center and Research, Inc.
Miami, Florida
Veritas Research Corporation
Miami Lakes, Florida
Harmony Clinical Research Inc.
North Miami Beach, Florida
Compass Research, LLC
Orlando, Florida
Clinical Research Center, LLC
Royal Palm Beach, Florida
Meridien Research, Inc.
St. Petersburg, Florida
Meridian Clinical Research, LLC
Tampa, Florida
Palm Beach Research Center
West Palm Beach, Florida
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.